Yongxia Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongxia Yang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Cuiling Qi
School of Life Sciences and Biopharmaceuticals, Guangdong Pharmaceutical University a , Guangzhou, 510006, P. R. China+86-20-3935-2126 +86-20-3935-2126
1 shared publicationHuaguo Liang
College of Life Sciences and Biopharmaceuticals, PR China
1 shared publicationJiangchao Li
School of Life Sciences and Biopharmaceuticals, Guangdong Pharmaceutical University a , Guangzhou, 510006, P. R. China+86-20-3935-2126 +86-20-3935-2126
1 shared publication- Lijing Wang
School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou, China
1 shared publication Lingyun Zheng
School of Life Sciences and Biopharmaceuticals, Guangdong Pharmaceutical University a , Guangzhou, 510006, P. R. China+86-20-3935-2126 +86-20-3935-2126
1 shared publicationQian Li
College of Life Sciences and Biopharmaceuticals, PR China
1 shared publication
Latest Publications
- 6 March 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 214, 114711
An integrated metabonomics study to reveal the inhibitory effect and metabolism regulation of taurine on breast cancer
- 6 March 2022
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 214, 114711
An integrated metabonomics study to reveal the inhibitory effect and metabolism regulation of taurine on breast cancer
- 3 December 2021
- Published by Oxford University Press (OUP) in Molecular Omics
- Vol. 18 (2) , 167-177
1H-NMR based metabolic study of MMTV-PyMT mice along with pathological progress to screen biomarkers for the early diagnosis of breast cancer
A 1H NMR-based metabonomic approach was applied to monitor the alterations of serum metabolic profiles in MMTV-PyMT transgenic mice to detect the dynamic changes associated with the pathological process and explore the early-stage biomarkers. The 1H NMR spectra of sera samples from four different stages in MMTV-PyMT mice including hyperplasia, adenoma, early carcinoma and late carcinoma stages were recorded and analyzed using multivariate statistical techniques. The results showed that the increased levels of lipid and lactate, and decreased leucine/isoleucine, valine, methionine, glutamine, creatine, PC/GPC, taurine and glucose were of significance for the early carcinoma stage. As the disease progressed (late carcinoma stage), the metabolic profiles changed significantly; some were negatively regulated compared with those at the early carcinoma stage, such as lipid, leucine/isoleucine, methionine and creatine, accompanied by other new metabolite changes of alanine, pyruvate, glutamate, citrate, aspartate, myo-inositol, 3-methylhistidine and formate. It is important to note that breast cancer patients and the early carcinoma stage of MMTV-PyMT mice had some similar metabolite changes, including lipid, lactate, glutamine, creatine, taurine and glucose, which were determined to be of great value for the early clinical diagnosis of breast cancer. The findings from this study provided valuable biomarkers for the early clinical diagnosis of breast cancer, and showed the potential power of integrating NMR techniques and pattern recognition methods for the analysis of the biochemical changes under certain pathophysiological conditions.
- 3 December 2021
- Published by Oxford University Press (OUP) in Molecular Omics
- Vol. 18 (2) , 167-177
1H-NMR based metabolic study of MMTV-PyMT mice along with pathological progress to screen biomarkers for the early diagnosis of breast cancer
A 1H NMR-based metabonomic approach was applied to monitor the alterations of serum metabolic profiles in MMTV-PyMT transgenic mice to detect the dynamic changes associated with the pathological process and explore the early-stage biomarkers. The 1H NMR spectra of sera samples from four different stages in MMTV-PyMT mice including hyperplasia, adenoma, early carcinoma and late carcinoma stages were recorded and analyzed using multivariate statistical techniques. The results showed that the increased levels of lipid and lactate, and decreased leucine/isoleucine, valine, methionine, glutamine, creatine, PC/GPC, taurine and glucose were of significance for the early carcinoma stage. As the disease progressed (late carcinoma stage), the metabolic profiles changed significantly; some were negatively regulated compared with those at the early carcinoma stage, such as lipid, leucine/isoleucine, methionine and creatine, accompanied by other new metabolite changes of alanine, pyruvate, glutamate, citrate, aspartate, myo-inositol, 3-methylhistidine and formate. It is important to note that breast cancer patients and the early carcinoma stage of MMTV-PyMT mice had some similar metabolite changes, including lipid, lactate, glutamine, creatine, taurine and glucose, which were determined to be of great value for the early clinical diagnosis of breast cancer. The findings from this study provided valuable biomarkers for the early clinical diagnosis of breast cancer, and showed the potential power of integrating NMR techniques and pattern recognition methods for the analysis of the biochemical changes under certain pathophysiological conditions.